BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) FY Conference Transcript

Summary of BridgeBio Oncology Therapeutics FY Conference Call Company Overview - Company: BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) - Event: FY Conference on December 02, 2025 - Speakers: Eli Wallace (CEO), Uneek Mehra (CFO) Key Points Clinical Pipeline - Focus: Development of small molecules targeting RAS and PI3K alpha oncogenes - Programs: 1. BBO-8520: KRAS G12C on/off inhibitor with high affinity, currently in phase one clinical development 2. BBO-10203: RAS PI3K alpha breaker, a novel protein-protein interaction inhibitor 3. BBO-11818: Pan-KRAS inhibitor, also in phase one clinical development [5][6][37] BBO-8520 Highlights - Differentiation: Inhibits both on and off states of KRAS, unlike first-generation inhibitors which only target the off state [7][9] - Efficacy Data: - 60% confirmed overall response rate observed in early cohorts - No grade three toxicities or liver toxicities reported [11][12] - Combination Potential: Positioned as a combination agent with pembrolizumab, with ongoing dose escalation studies [14][16] BBO-10203 Insights - Mechanism: Inhibits PI3K alpha AKT signaling specifically when driven by RAS, without affecting glucose homeostasis [26][27] - Target Tumors: HER2-amplified breast cancer, hormone receptor-positive breast cancer, and KRAS mutants [28][29] - Expected Data Release: First half of 2026, focusing on monotherapy and early combination data [29] BBO-11818 Overview - Target: Pan-KRAS inhibitor, aiming for high levels of inhibition while sparing HRAS and NRAS to maintain therapeutic index [37][38] - Expected Data Release: Second half of 2026, focusing on dose escalation across various tumor types [40] Financial Position - Cash Reserves: $468 million as of September 30, 2025, expected to last until 2028 [49] - Capital Allocation: Dynamic allocation based on data emerging from all three programs, with potential for strategic partnerships for further development [50][51] Strategic Considerations - Market Positioning: Acknowledgment of competition, particularly from RevMed and their KRAS inhibitor, while emphasizing the broader application of BridgeBio's therapies across multiple cancer types [43][44] - Combination Therapy Potential: Emphasis on the ability to combine therapies targeting MAPK and PI3K pathways safely, which has been challenging in the past [46] Additional Notes - Safety Data: Focus on differentiated safety profiles, particularly regarding glucose metabolism and liver toxicity [35] - Resistance Mechanisms: No significant resistance mechanisms identified yet in preclinical studies [36] This summary encapsulates the critical insights and developments discussed during the conference call, highlighting BridgeBio's innovative approach to oncology therapeutics and its strategic positioning in the market.